China Reform Health Management and Services Group (000503) Fundamentals 2026 — Revenue Analysis | SniperIQ
China Reform Health Management and Services Group (000503) is a CN-listed Healthcare company in Medical - Healthcare Plans with a market capitalization of ¥6.2B, trading at ¥6.36 on the SHZ. This SniperIQ fundamentals page covers China Reform Health Management and Services Group's valuation, profitability (net margin -116.1%), revenue (¥350M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Reform Health Management and Services Group's market cap?
China Reform Health Management and Services Group (000503) has a market capitalization of approximately ¥6.2B, trading at ¥6.36 on the SHZ. Market cap moves with the live share price.
What is China Reform Health Management and Services Group's P/E ratio?
China Reform Health Management and Services Group's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Reform Health Management and Services Group?
China Reform Health Management and Services Group runs a net profit margin of -116.1%, a gross margin of 22.4%, and an operating margin of -117.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Reform Health Management and Services Group generate?
China Reform Health Management and Services Group reported revenue of ¥350M for fiscal year 2025, with net income of -¥404M and earnings per share (EPS) of -0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Reform Health Management and Services Group pay a dividend?
China Reform Health Management and Services Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is China Reform Health Management and Services Group financially healthy?
China Reform Health Management and Services Group carries a debt-to-equity ratio of 0.43x and a current ratio of 1.96x, with a market beta of 0.59. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Reform Health Management and Services Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Reform Health Management and Services Group (000503) the key facts are: market cap ¥6.2B, revenue ¥350M, 52-week range 6.09-12.54. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Reform Health Management and Services Group's full fundamentals live
Get China Reform Health Management and Services Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.